ZOMIG Nasal Spray is the first and only nasal spray approved for adolescent migraine patients (ages 12-17 years). Freedom from headache pain is possible for some adolescents with ZOMIG Nasal Spray. In a multicenter, randomized, double-blind, placebo-controlled study, almost twice as many adolescent migraine patients were pain free with ZOMIG Nasal Spray 5 mg vs placebo at 2 hours (30% vs 17%; P<0.05).
One spray may be all most teens need. Nearly 80% of adolescents who used ZOMIG Nasal Spray 5 mg did not need to use a second dose or another medicine with 24 hours compared with 68.4% for placebo. Within 4 hours, 71% of patients returned to normal activities using either ZOMIG Nasal Spray 5 mg or 2.5 mg vs 57% for placebo.
When a migraine strikes, help your patients fast forward to migraine relief with ZOMIG Nasal Spray.
Please see Full Prescribing Information at ZomigHCP.com.
References 1. FDA approves ZOMIG (zolmitriptan) Nasal Spray for migraine in pediatric patients (ages 12-17) [press release]; June 16, 2015. 2. Date on File, Impax Laboratories, LLC.